hey seriously please get yourself checked up, looks like you are deliberately being obtuse or you are just googling the info, my advice get some TAFE course in science, In a typical Phase I dose‐escalation design, a DLT must appear in at least 2/6 patients at a given dose before the cohort is considered too toxic. investigators withdrew that single patient, re‐evaluated the safety data, and deemed it reasonable to continue enrolling more patients at that same dose or adjust the dose accordingly.
Do you think PD1 alone has this observation (what ever may be the reason) in Keytruda study 41 (7 %) developed pneumonitis with different grades, and there were clear indication of pneumonitis death with Keytruda, now go figure what is adoption rate and how successful it is
IMU Price at posting:
1.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)